Skip to main content
SpringerLink
Log in

Genetics of Renal Cell Carcinoma

  • Chapter
  • First Online:
Diagnosis and Surgical Management of Renal Tumors

  • 753 Accesses

Abstract

Renal cell carcinoma (RCC) includes a number of genetically distinct histological subtype. An understanding of the genetic basis of RCC has led to distinct treatment paradigms in both the surgical management of localized disease and in the treatment of advanced disease with systemic therapy. While insights into the genetic basis of RCC have been gleaned from the study of patients with hereditary cancer syndromes, many treatment principles can be extrapolated to patients with sporadic forms of the disease. This chapter reviews the genetics of both sporadic and hereditary RCC with a special emphasis on the translation of genetic insights into treatment approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

    Article  PubMed  Google Scholar 

  2. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105.

    Article  PubMed  Google Scholar 

  3. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 2012;22:2089–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kletscher BA, Qian J, Bostwick DG, Andrews PE, Zincke H. Prospective analysis of multifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy. J Urol. 1995;153:904–6.

    Article  CAS  PubMed  Google Scholar 

  5. Whang M, O’Toole K, Bixon R, Brunetti J, Ikeguchi E, Olsson CA, et al. The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J Urol. 1995;154:968–70; discussion 70–1.

    Article  CAS  PubMed  Google Scholar 

  6. Gudbjartsson T, Jonasdottir TJ, Thoroddsen A, Einarsson GV, Jonsdottir GM, Kristjansson K, et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer. 2002;100:476–9.

    Article  CAS  PubMed  Google Scholar 

  7. Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin N Am. 2012;39:133–48, v.

    Article  Google Scholar 

  8. Ball MW, Singer EA, Srinivasan R. Renal cell carcinoma: molecular characterization and evolving treatment paradigms. Curr Opin Oncol. 2017;29:201–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15:55–64.

    Article  CAS  PubMed  Google Scholar 

  11. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010;40:294–309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–5.

    Article  CAS  PubMed  Google Scholar 

  13. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2:423–7.

    Article  CAS  PubMed  Google Scholar 

  14. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292:464–8.

    Article  CAS  PubMed  Google Scholar 

  15. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–72.

    Article  CAS  PubMed  Google Scholar 

  16. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673–82.

    Article  CAS  PubMed  Google Scholar 

  17. Nielsen SM, Rhodes L, Blanco I, Chung WK, Eng C, Maher ER, et al. Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol. 2016;34:2172–81.

    Article  CAS  PubMed  Google Scholar 

  18. Latif F, Tory K, Gnarra JR, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20.

    Article  CAS  PubMed  Google Scholar 

  19. Tory K, Brauch H, Linehan WM, Barba D, Oldfield E, Filling-Katz M, et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst. 1989;81:1097–101.

    Article  CAS  PubMed  Google Scholar 

  20. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002;1:459–68.

    Article  CAS  PubMed  Google Scholar 

  21. Beroud C, Joly D, Gallou C, Staroz F, Orfanelli MT, Junien C. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 1998;26:256–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Nordstrom-O’Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31:521–37.

    PubMed  Google Scholar 

  23. Duffey BG, Choyke PL, Glenn G, Grubb RL, Venzon D, Linehan WM, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172:63–5.

    Article  PubMed  Google Scholar 

  24. Singer EA, Vourganti S, Lin KY, Gupta GN, Pinto PA, Rastinehad AR, et al. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup. J Urol. 2012;188:2084–8.

    Article  PubMed  Google Scholar 

  25. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.

    Article  CAS  Google Scholar 

  26. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44:751–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013;19:3259–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46:225–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ball MW, Gorin MA, Drake CG, Hammers HJ, Allaf ME. The landscape of whole-genome alterations and pathologic features in genitourinary malignancies: an analysis of the cancer genome atlas. Eur Urol Focus. 2017;3:584.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Ball MW, Johnson MH, Gorin MA, Rodriguez M, Diaz LA, Haffner M, et al. Clinical, pathologic, and genomic profiles of exceptional responders to anti−PD1 therapy in renal cell carcinoma. J Clin Oncol. 2016;34:625.

    Article  Google Scholar 

  34. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med. 1979;301:592–5.

    Article  CAS  PubMed  Google Scholar 

  35. van Kessel AG, Wijnhoven H, Bodmer D, Eleveld M, Kiemeney L, Mulders P, et al. Renal cell cancer: chromosome 3 translocations as risk factors. J Natl Cancer Inst. 1999;91:1159–60.

    Article  PubMed  Google Scholar 

  36. Rodriguez-Perales S, Melendez B, Gribble SM, Valle L, Carter NP, Santamaria I, et al. Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. Hum Mol Genet. 2004;13:983–90.

    Article  CAS  PubMed  Google Scholar 

  37. Farley MN, Schmidt LS, Mester JL, Pena-Llopis S, Pavia-Jimenez A, Christie A, et al. Germline BAP1 mutation predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res. 2013;11:1061.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89:285–94.

    Article  CAS  PubMed  Google Scholar 

  39. Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d’Enghien C, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92:974–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13:153–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Leung C, Pan S, Shuch B. Management of renal cell carcinoma in young patients and patients with hereditary syndromes. Curr Opin Urol. 2016;26:396–404.

    Article  PubMed  Google Scholar 

  42. Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol. 2016;71:606.

    Article  PubMed  Google Scholar 

  43. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–45.

    Article  PubMed  CAS  Google Scholar 

  44. Zbar B, Tory K, Merino MJ, Schmidt LS, Glenn GM, Choyke P, et al. Hereditary papillary renal cell carcinoma. J Urol. 1994;151:561–6.

    Article  CAS  PubMed  Google Scholar 

  45. Lubensky IA, Schmidt LS, Zhuang Z, Weirich G, Pack S, Zambrano N, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155:517–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ornstein DK, Lubensky IA, Venzon D, Zbar B, Linehan WM, Walther MM. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol. 2000;163:431–3.

    Article  CAS  PubMed  Google Scholar 

  47. Zbar B, Glenn GM, Lubensky IA, Choyke P, Magnusson G, Bergerheim U, et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol. 1995;153:907–12.

    Article  CAS  PubMed  Google Scholar 

  48. Schmidt LS, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 1998;58:1719–22.

    CAS  PubMed  Google Scholar 

  49. Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol. 2004;172:1256–61.

    Article  PubMed  Google Scholar 

  50. Schmidt LS, Duh FM, Chen F, Kishida T, Glenn GM, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73.

    Article  CAS  PubMed  Google Scholar 

  51. Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer. 1991;3:249–55.

    Article  CAS  PubMed  Google Scholar 

  52. Schmidt LS, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–50.

    Article  CAS  PubMed  Google Scholar 

  53. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–25.

    Article  CAS  PubMed  Google Scholar 

  54. Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci U S A. 2003;100:12654–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Jeffers M, Schmidt LS, Nakaigawa N, Webb CP, Weirich G, Kishida T, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A. 1997;94:11445–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A. 1998;95:14417–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Zhuang Z, Park WS, Pack S, Schmidt LS, Pak E, Pham T, et al. Trisomy 7 – harboring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet. 1998;20:66–9.

    Article  CAS  PubMed  Google Scholar 

  58. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98:3387–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Merino MJ, Torres-Cabala C, Pinto PA, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31:1578–85.

    Article  PubMed  Google Scholar 

  60. Grubb RL III, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177:2074–80.

    Article  CAS  PubMed  Google Scholar 

  61. Schmidt LS, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renov Dis. 2014;7:253–60.

    Article  Google Scholar 

  62. Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95–106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006;43:18–27.

    Article  CAS  PubMed  Google Scholar 

  64. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406–10.

    Article  CAS  PubMed  Google Scholar 

  65. Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell. 2011;20:315–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Yang Y, Lane AN, Ricketts CJ, Sourbier C, Wei MH, Shuch B, et al. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. PLoS One. 2013;8:e72179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8:143–53.

    Article  CAS  PubMed  Google Scholar 

  68. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011;20:524–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011;20:511–23.

    Article  CAS  PubMed  Google Scholar 

  70. Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol. 1977;113:1674–7.

    Article  CAS  PubMed  Google Scholar 

  71. Zbar B, Alvord WG, Glenn GM, Turner M, Pavlovich CP, Schmidt LS, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:393–400.

    PubMed  Google Scholar 

  72. Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dub‚ syndrome. Am J Hum Genet. 2005;76:1023–33.

    Article  CAS  PubMed  Google Scholar 

  73. Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocke CD, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45:321–31.

    Article  CAS  PubMed  Google Scholar 

  74. Schmidt LS, Linehan WM. Molecular genetics and clinical features of Birt-Hogg-Dube syndrome. Nat Rev Urol. 2015;12:558–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, et al. Renal tumors in the Birt-Hogg-Dub‚ syndrome. Am J Surg Pathol. 2002;26:1542–52.

    Article  PubMed  Google Scholar 

  76. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn GM, Turner ML, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2:157–64.

    Article  CAS  PubMed  Google Scholar 

  77. Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst. 2005;97:931–5.

    Article  CAS  PubMed  Google Scholar 

  78. Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, et al. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling. Mol Cancer. 2010;9:160.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014;11:465–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32:103–13.

    Article  PubMed  Google Scholar 

  81. Bertolotto C, Lesueur F, Giuliano S, Strub T, de LM, Bille K, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480:94–8.

    Article  CAS  PubMed  Google Scholar 

  82. Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–96.

    Article  CAS  Google Scholar 

  83. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–56.

    Article  CAS  PubMed  Google Scholar 

  84. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149:1–8.

    Google Scholar 

  85. Henske EP, Jozwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035.

    Article  PubMed  Google Scholar 

  86. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Tsai JD, Wei CC, Yang SH, Fan HC, Hsu CC, Tung MC, et al. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: a preliminary report. Nephrology (Carlton). 2017;22:1017–22.

    Article  CAS  Google Scholar 

  88. Kothary N, Soulen MC, Clark TW, Wein AJ, Shlansky-Goldberg RD, Crino PB, et al. Renal angiomyolipoma: long-term results after arterial embolization. J Vasc Interv Radiol. 2005;16:45–50.

    Article  PubMed  Google Scholar 

  89. Cristescu M, Abel EJ, Wells S, Ziemlewicz TJ, Hedican SP, Lubner MG, et al. Percutaneous microwave ablation of renal angiomyolipomas. Cardiovasc Intervent Radiol. 2016;39:433–40.

    Article  PubMed  Google Scholar 

  90. Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol. 2012. https://doi.org/10.1016/j.juro.2012.08.030.

    Article  CAS  PubMed  Google Scholar 

  91. Gill AJ, Hes O, Papathomas T, Sedivcova M, Tan PH, Agaimy A, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38:1588–602.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Mark W. Ball & W. Marston Linehan

Authors
  1. Mark W. Ball
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Marston Linehan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark W. Ball .

Editor information

Editors and Affiliations

  1. The James Buchanan Brady Urological, Institute and Department of Urology, Johns Hopkins University School of Medic, Baltimore, MD, USA

    Michael A. Gorin

  2. The James Buchanan Brady Urological, Institute and Department of Urology, Johns Hopkins University School of Medic, Baltimore, MD, USA

    Mohamad E. Allaf

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ball, M.W., Linehan, W.M. (2019). Genetics of Renal Cell Carcinoma. In: Gorin, M., Allaf, M. (eds) Diagnosis and Surgical Management of Renal Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-92309-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92309-3_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92308-6

  • Online ISBN: 978-3-319-92309-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation